China Osteoporosis Drugs industry has expanded over the years with continuous R&D activities and high prevalence of bone-related diseases

In the past, the treatment of osteoporosis was limited to surgery and drugs. The advent of new technology and an understanding of bone biology allowed for the development of minimally invasive, drug-free (nanoluminescent) surgical treatments. Although bone loss is most commonly found in elderly individuals, it can affect anyone from young to middle age. For people suffering from osteoporosis, drugs are an option for managing the disease. In Germany, the prevalence of osteoporosis in individuals aged 50 years and above is around 26% overall and 39% in women.

The two medications most often used for osteoporosis drugs are indemnamycin and calcitonin. These medications are also known as anticoagulants and both work by binding calcium in the blood. When these binding agents become less available, they allow for more fluid absorption through the bloodstream, and they stimulate bone formation. As a result of these actions, bone mass is enhanced, and fractures are avoided. Another osteoporosis drug is Periostat. This osteoporosis drug, like aspirin, is designed to prevent the breakdown of vitamin D, which enhances bone formation. Calcium supplements are commonly taken by postmenopausal women to promote good bone formation.

There are several newer China osteoporosis drugs on the market today. One is romosozumab, which is marketed under several different brand names. It's been known to slow down the process of osteoporosis by inducing bone formation. Although studies have shown that romosozumab has some osteoporosis benefits, more research is needed to definitively prove its effectiveness. Other medications used to treat osteoporosis have had similar results, including Accutane. Another China osteoporosis drug available is Thalassemia, which is a genetic disease that prevents the production of an enzyme that keeps bones strong and flexible. Recently, in January 2019, the Japanese Ministry of Health, Labor, and Welfare approved Amgen and UCB Pharma’s monoclonal antibody romosozumab drug indicated for osteoporosis.